---
title: 'Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies:
  Clinical Implications and Limitations'
date: '2024-04-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38672680/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240427180604&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Chimeric antigen receptor (CAR) T-cell therapy has become a powerful
  treatment option in B-cell and plasma cell malignancies, and many patients have
  benefited from its use. To date, six CAR T-cell products have been approved by the
  FDA and EMA, and many more are being developed and investigated in clinical trials.
  The whole field of adoptive cell transfer has experienced an unbelievable development
  process, and we are now at the edge of a new era of immune therapies that will have
  its ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in clinical trials. The whole field of adoptive cell transfer has experienced an unbelievable development process, and we are now at the edge of a new era of immune therapies that will have its ...